Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Rhea-AI Summary

Kalaris (Nasdaq: KLRS) announced that company management will present at the Stifel 2025 Annual Healthcare Conference on Thursday, November 13, 2025 from 3:20–3:50pm ET at the Lotte New York Palace Hotel in New York, NY.

Speakers listed are Andrew Oxtoby, CEO, and Matthew Feinsod, CMO. Management will be available for one-on-one meetings during the conference; interested parties should contact their conference representative to arrange a meeting.

News Market Reaction – KLRS

-2.67%

1 alert

-2.67% Session close to close

$95.76M Market Cap

0.3x Rel. Volume

In the Oct 30 session, KLRS declined 2.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference.

Details:

• Type: Company presentation
• Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
• Date: Thursday, November 13, 2025
• Time: 3:20 – 3:50pm ET
• Location: Lotte New York Palace Hotel, New York, NY
  
  

Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.

About Kalaris

Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

For more information, visit www.kalaristx.com.

Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com

FAQ

When is Kalaris (KLRS) presenting at the Stifel 2025 Annual Healthcare Conference?

Kalaris will present on Thursday, November 13, 2025 from 3:20–3:50pm ET.

Who will speak for Kalaris (KLRS) at the November 13, 2025 presentation?

The listed speakers are Andrew Oxtoby, CEO, and Matthew Feinsod, CMO.

Where is the Kalaris (KLRS) presentation being held on November 13, 2025?

The presentation location is the Lotte New York Palace Hotel in New York, NY.

Will Kalaris (KLRS) hold one-on-one meetings at the Stifel 2025 conference?

Yes. Management will be available for one-on-one meetings; attendees should contact their conference representative to arrange meetings.

Will Kalaris (KLRS) release clinical data during the Stifel 2025 presentation on November 13, 2025?

The announcement confirms a company presentation but does not specify any clinical data or presentation materials.

How can investors access Kalaris (KLRS) presentation materials from the Stifel 2025 conference?

The announcement does not provide distribution details; interested parties should contact their conference representative or Kalaris investor relations for access.